Stages in the development of Parkinson’s disease-related pathology

被引:0
|
作者
Heiko Braak
Estifanos Ghebremedhin
Udo Rüb
Hansjürgen Bratzke
Kelly Del Tredici
机构
[1] J.W. Goethe University,Institute for Clinical Neuroanatomy
[2] J.W. Goethe University,Institute for Forensic Medicine
来源
Cell and Tissue Research | 2004年 / 318卷
关键词
Alpha-synuclein; Lewy bodies; Lewy neurites; Parkinson’s disease; Pathoarchitectonics; Staging;
D O I
暂无
中图分类号
学科分类号
摘要
The synucleinopathy, idiopathic Parkinson’s disease, is a multisystem disorder that involves only a few predisposed nerve cell types in specific regions of the human nervous system. The intracerebral formation of abnormal proteinaceous Lewy bodies and Lewy neurites begins at defined induction sites and advances in a topographically predictable sequence. As the disease progresses, components of the autonomic, limbic, and somatomotor systems become particularly badly damaged. During presymptomatic stages 1–2, inclusion body pathology is confined to the medulla oblongata/pontine tegmentum and olfactory bulb/anterior olfactory nucleus. In stages 3–4, the substantia nigra and other nuclear grays of the midbrain and forebrain become the focus of initially slight and, then, severe pathological changes. At this point, most individuals probably cross the threshold to the symptomatic phase of the illness. In the end-stages 5–6, the process enters the mature neocortex, and the disease manifests itself in all of its clinical dimensions.
引用
收藏
页码:121 / 134
页数:13
相关论文
共 50 条
  • [1] Stages in the development of Parkinson's disease-related pathology
    Braak, H
    Ghebremedhin, E
    Rüb, U
    Bratzke, H
    Del Tredici, K
    CELL AND TISSUE RESEARCH, 2004, 318 (01) : 121 - 134
  • [2] The role of neurotransmitters in the development of Parkinson's disease-related psychosis
    Factor, S. A.
    McDonald, W. M.
    Goldstein, F. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (10) : 1244 - 1254
  • [3] Relationship of Apolipoprotein E to Parkinson's disease-related alpha-synuclein pathology
    Parkkinen, L.
    Joachim, C.
    Esiri, M. M.
    Ansorge, O.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2013, 39 : 37 - 37
  • [4] Coping with disease-related stressors in Parkinson's disease
    Frazier, LD
    GERONTOLOGIST, 2000, 40 (01): : 53 - 63
  • [5] Is Parkinson's disease-related mortality declining?
    Haberfeld, E.
    Louis, E. D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (09) : 964 - 965
  • [6] Coadministration of 6-Shogaol and Levodopa Alleviates Parkinson's Disease-Related Pathology in Mice
    Kim, Jin Hee
    Kim, Jin Se
    Ju, In Gyoung
    Huh, Eugene
    Choi, Yujin
    Lee, Seungmin
    Cho, Jun-Young
    Park, Boyoung Y.
    Oh, Myung Sook
    BIOMOLECULES & THERAPEUTICS, 2024, 32 (05) : 523 - 530
  • [7] A Novel NOX Inhibitor Treatment Attenuates Parkinson's Disease-Related Pathology in Mouse Models
    Ghosh, Anurupa A.
    Verma, Dinesh Kumar
    Cabrera, Gabriela
    Ofori, Kwadwo
    Hernandez-Quijada, Karina
    Kim, Jae-Kwan
    Chung, Joo Hee
    Moore, Michael
    Moon, Sung Hwan
    Seo, Jong Bok
    Kim, Yong-Hwan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (08)
  • [8] Parkinson's disease pathology and vascular pathology contribute to the development of Parkinson's disease dementia
    Rosenthal, L. S.
    Troncoso, J. C.
    Pletnikova, O.
    Bassett, S. S.
    Pontone, G. M.
    Mari, Z.
    Dawson, T. M.
    MOVEMENT DISORDERS, 2014, 29 : S361 - S361
  • [9] Prevention of Parkinson's disease-related sudden death
    Scorza, Fulvio A.
    de Almeida, Antonio Carlos G.
    Scorza, Carla A.
    Finsterer, Josef
    CLINICS, 2021, 76
  • [10] Parkinson's Disease-Related Genes and Lipid Alteration
    Fais, Milena
    Dore, Antonio
    Galioto, Manuela
    Galleri, Grazia
    Crosio, Claudia
    Iaccarino, Ciro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (14)